Utilization of a Label-Free Real-Time Cell Analysis Technology for Cancer Immunotherapy Applications

Utilization of a Label-Free Real-Time Cell Analysis Technology for Cancer Immunotherapy Applications

Download slide deck

About this Webinar

Cancer immunotherapies harness and enhance the innate powers of the immune system to eliminate cancer cells. They can be divided into three major categories: cytokines/immunomodulation agents, monoclonal antibodies, and cell therapies.  Though traditional end-point assays can be used to evaluate the efficacy of immune cell killing in vitro, an assay providing long-term killing-kinetics reminiscent of the “serial killing” nature of immune cells in vivo has remained elusive.

During this webinar, Dr. Abassi will demonstrate the advantages of utilizing the label-free real-time cell analysis (RTCA) technology as an automated homogeneous screening platform to evaluate immune cell killing in vitro.

Additional topics will include:

  1. Overview of cancer immunotherapies
  2. The xCELLigence Real-Time Cell Analysis (RTCA) assay principle
  3. Case Studies: Applications of RTCA in monitoring immune mediated tumor cell killing, e.g., NK cells, cytolytic T cells, ADCC and CAR-T
Featured Speaker 

yamaYama A. Abassi, Ph.D.
Vice President of ACEA Biosciences, Inc.

Dr. Yama A. Abassi is Vice President of ACEA Biosciences. He received his undergraduate degree in biochemistry with honors from the State University of New York/Stony Brook in 1992, and  a PhD in  Molecular, Cell, and  Developmental Biology from the  University of  California at Santa Barbara in 1999. Dr. Abassi joined the Burnham Institute for Cancer Research as an NIH post-doctoral fellow in 1999 and spent the next few years studying oncogene signaling pathways and their role in cancer biology.

Dr. Abassi joined ACEA Biosciences in 2003 to help develop a new technology for studying cells using microelectronics. Dr. Abassi’s efforts in this field have earned him numerous publications and patents and have led to the successful development and commercialization of the xCELLigence Real-Time Cell Analysis (RTCA) instrument globally. Dr. Abassi continues to pursue his research interests in developing technologies and applications for in vitro cell-based assays in different fields, including cancer immunotherapy.  He also oversees several collaborations with the US EPA that focus on assessing the impact of toxic environmental compounds (in particular, compounds which may interfere with estrogen signaling pathways).